Parfrey PS - Search Results

1

Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s).

Drüeke TB, Parfrey PS. Drüeke TB, et al. Among authors: parfrey ps. Kidney Int. 2012 Nov;82(9):952-60. doi: 10.1038/ki.2012.270. Epub 2012 Aug 1. Kidney Int. 2012. PMID: 22854645 Review.

2

Comparative hospitalization of hemodialysis and peritoneal dialysis patients in Canada.

Murphy SW, Foley RN, Barrett BJ, Kent GM, Morgan J, Barré P, Campbell P, Fine A, Goldstein MB, Handa SP, Jindal KK, Levin A, Mandin H, Muirhead N, Richardson RM, Parfrey PS. Murphy SW, et al. Among authors: parfrey ps. Kidney Int. 2000 Jun;57(6):2557-63. doi: 10.1046/j.1523-1755.2000.00115.x. Kidney Int. 2000. PMID: 10844625

3

Autosomal recessive Bardet-Biedl syndrome: first-degree relatives have no predisposition to metabolic and renal disorders.

Webb MP, Dicks EL, Green JS, Moore SJ, Warden GM, Gamberg JS, Davidson WS, Young TL, Parfrey PS. Webb MP, et al. Among authors: parfrey ps. Kidney Int. 2009 Jul;76(2):215-23. doi: 10.1038/ki.2009.116. Epub 2009 Apr 15. Kidney Int. 2009. PMID: 19367329

4

Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy.

Foley RN, Parfrey PS, Morgan J, Barré PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA. Foley RN, et al. Among authors: parfrey ps. Kidney Int. 2000 Sep;58(3):1325-35. doi: 10.1046/j.1523-1755.2000.00289.x. Kidney Int. 2000. PMID: 10972697 Clinical Trial.

5

Comparative mortality of hemodialysis and peritoneal dialysis in Canada.

Murphy SW, Foley RN, Barrett BJ, Kent GM, Morgan J, Barré P, Campbell P, Fine A, Goldstein MB, Handa SP, Jindal KK, Levin A, Mandin H, Muirhead N, Richardson RM, Parfrey PS. Murphy SW, et al. Among authors: parfrey ps. Kidney Int. 2000 Apr;57(4):1720-6. doi: 10.1046/j.1523-1755.2000.00017.x. Kidney Int. 2000. PMID: 10760108

6

Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.

Skali H, Lin J, Pfeffer MA, Chen CY, Cooper ME, McMurray JJ, Nissenson AR, Remuzzi G, Rossert J, Parfrey PS, Scott-Douglas NW, Singh AK, Toto R, Uno H, Ivanovich P. Skali H, et al. Among authors: parfrey ps. Am J Kidney Dis. 2013 Feb;61(2):238-46. doi: 10.1053/j.ajkd.2012.08.043. Epub 2012 Nov 16. Am J Kidney Dis. 2013. PMID: 23159232 Clinical Trial.

7

On peginesatide and anemia treatment in CKD.

Parfrey PS, Warden G, Barrett BJ. Parfrey PS, et al. Am J Kidney Dis. 2013 Oct;62(4):659-61. doi: 10.1053/j.ajkd.2013.05.008. Epub 2013 Jun 28. Am J Kidney Dis. 2013. PMID: 23810692 No abstract available.

8

Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial.

Floege J, Tsirtsonis K, Iles J, Drueke TB, Chertow GM, Parfrey P. Floege J, et al. Kidney Int. 2018 Jun;93(6):1475-1482. doi: 10.1016/j.kint.2017.12.014. Epub 2018 Mar 7. Kidney Int. 2018. PMID: 29525393 Clinical Trial.

9

Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors.

Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Harnett JD, et al. Among authors: parfrey ps. Kidney Int. 1995 Mar;47(3):884-90. doi: 10.1038/ki.1995.132. Kidney Int. 1995. PMID: 7752588 Clinical Trial.

10

Chronic hepatitis in end-stage renal disease: comparison of HBsAg-negative and HBsAg-positive patients.

Parfrey PS, Farge D, Forbes RD, Dandavino R, Kenick S, Guttmann RD. Parfrey PS, et al. Kidney Int. 1985 Dec;28(6):959-67. doi: 10.1038/ki.1985.224. Kidney Int. 1985. PMID: 3936966

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results